276 related articles for article (PubMed ID: 29194852)
21. Interrelationship of circulating matrix metalloproteinase-9, TNF-α, and OPG/RANK/RANKL systems in COPD patients with osteoporosis.
Zhang PF; Pan L; Luo ZY; Zhao HJ; Cai SX
COPD; 2013 Dec; 10(6):650-6. PubMed ID: 23845033
[TBL] [Abstract][Full Text] [Related]
22. Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease.
Ugay L; Kochetkova E; Nevzorova V; Maistrovskaia Y
Chin Med J (Engl); 2016 Jul; 129(14):1696-703. PubMed ID: 27411457
[TBL] [Abstract][Full Text] [Related]
23. Receptor Activator of Nuclear Factor κ-Β Ligand/Osteoprotegerin Axis in Adults with Hb S/β-Thalassemia and β-Thalassemia Trait.
Tombak A; Boztepe B; Akbayir S; Dogru G; Sungur MA
Hemoglobin; 2020 Sep; 44(5):334-337. PubMed ID: 32873083
[TBL] [Abstract][Full Text] [Related]
24. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
[TBL] [Abstract][Full Text] [Related]
25. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
Terpos E; Fragiadaki K; Konsta M; Bratengeier C; Papatheodorou A; Sfikakis PP
Clin Exp Rheumatol; 2011; 29(6):921-5. PubMed ID: 22032557
[TBL] [Abstract][Full Text] [Related]
26. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
Kyvernitakis I; Rachner TD; Urbschat A; Hars O; Hofbauer LC; Hadji P
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1671-80. PubMed ID: 24903965
[TBL] [Abstract][Full Text] [Related]
27. Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis.
Wang A; Karunasinghe N; Plank LD; Zhu S; Osborne S; Brown C; Bishop K; Schwass T; Tijono S; Holmes M; Masters J; Huang R; Keven C; Ferguson LR; Lawrenson R
Sci Rep; 2021 Jul; 11(1):14905. PubMed ID: 34290287
[TBL] [Abstract][Full Text] [Related]
28. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.
Xu S; Wang Y; Lu J; Xu J
Rheumatol Int; 2012 Nov; 32(11):3397-403. PubMed ID: 22057136
[TBL] [Abstract][Full Text] [Related]
29. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
[TBL] [Abstract][Full Text] [Related]
30. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.
Chiarito M; Piacente L; Chaoul N; Pontrelli P; D'Amato G; Grandone A; Russo G; Street ME; Wasniewska MG; Brunetti G; Faienza MF
J Endocrinol Invest; 2022 Jun; 45(6):1255-1263. PubMed ID: 35237949
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
[TBL] [Abstract][Full Text] [Related]
32. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
33. Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Stuss M; Sewerynek E; Król I; Stępień-Kłos W; Jędrzejczyk S
Endokrynol Pol; 2016; 67(2):174-84. PubMed ID: 26884284
[TBL] [Abstract][Full Text] [Related]
34. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis.
Bai P; Sun Y; Jin J; Hou J; Li R; Zhang Q; Wang Y
Respir Res; 2011 Dec; 12(1):157. PubMed ID: 22176920
[TBL] [Abstract][Full Text] [Related]
35. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
Stern A; Laughlin GA; Bergstrom J; Barrett-Connor E
Eur J Endocrinol; 2007 May; 156(5):555-62. PubMed ID: 17468191
[TBL] [Abstract][Full Text] [Related]
36. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
37. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
38. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
[TBL] [Abstract][Full Text] [Related]
39. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
[TBL] [Abstract][Full Text] [Related]
40. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]